

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:43:03 ON 14 APR 2007

FILE 'EMBASE' ENTERED AT 16:43:24 ON 14 APR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:43:24 ON 14 APR 2007

FILE 'CAPLUS' ENTERED AT 16:43:24 ON 14 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:43:24 ON 14 APR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 16:43:24 ON 14 APR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'DISSABS' ENTERED AT 16:43:24 ON 14 APR 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'REGISTRY' ENTERED AT 16:43:24 ON 14 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

```
=> s "collectin fusion protein"
L1          4 "COLLECTIN FUSION PROTEIN"
```

=> s collectin AND TNF AND fusion
L2 3 COLLECTIN AND TNF AND FUSION

=> d 12 1-3

L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:817923 CAPLUS

DN 141:330784
TI Chimeric proteins comprising Ig Fc domain and receptor ligand-binding domain or ligand receptor-binding domain for treating autoimmune disease, AIDS, transplant rejection and inflammation

IN Walczak, Henning
PA Apogenix Biotechnology A.-G., Germany
SO PCT Int. Appl., 44 pp.

DT CODEN: Patent

LA Engl.

FAN.CNT 2

PATE

PI WO 2004085478 A2 20041007 WO 2004-EP3239 20040326
WO 2004085478 A3 20050106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG
 AU 2004224122 A1 20041007 AU 2004-224122 20040326
 CA 2520138 A1 20041007 CA 2004-2520138 20040326
 EP 1606318 A2 20051221 EP 2004-723552 20040326
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 PRAI EP 2003-6949 A 20030326
 WO 2004-EP3239 W 20040326

L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:10696 CAPLUS

DN 136:68702

TI Analysis of CD154 oligomerization on CD40 signaling using CD154-collectin fusion protein

IN Al-Shamkhani, Aymen; Glennie, Martin

PA Cancer Research Ventures Limited, UK

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000893	A1	20020103	WO 2001-GB2810	20010625
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2414342	A1	20020103	CA 2001-2414342	20010625
	EP 1297160	A1	20030402	EP 2001-945468	20010625
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004047873	A1	20040311	US 2003-312374	20031010
PRAI	GB 2000-15426	A	20000624		
	WO 2001-GB2810	W	20010625		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:435124 CAPLUS

DN 135:45182

TI Multimeric forms of TNF superfamily ligands

IN Kornbluth, Richard S.

PA USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	WO 2001042298	A1	20010614	WO 2000-US7380	20000320
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2393659	A1	20010614	CA 2000-2393659	20000320
	EP 1235853	A1	20020904	EP 2000-919485	20000320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AU 785297	B2	20070104	AU 2000-40167	20000320
	US 2005158831	A1	20050721	US 2005-87348	20050322
PRAI	US 1999-454223	A	19991209		
	US 1998-111471P	P	19981209		
	WO 2000-US7380	W	20000320		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s collectin AND TNFSF AND fusion
L3 1 COLLECTIN AND TNFSF AND FUSION

=> d 13 all

L3	ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN	2001:435124 CAPLUS
DN	135:45182
ED	Entered STN: 15 Jun 2001
TI	Multimeric forms of TNF superfamily ligands
IN	Kornbluth, Richard S.
PA	USA
SO	PCT Int. Appl., 73 pp.
	CODEN: PIXXD2
DT	Patent
LA	English
IC	ICM C07K014-00
	ICS A61K038-00
CC	15-2 (Immunochemistry)
	Section cross-reference(s): 3
FAN.CNT 1	
	PATENT NO. KIND DATE APPLICATION NO. DATE
PI	WO 2001042298 A1 20010614 WO 2000-US7380 20000320
	W: AU, CA, JP
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
	CA 2393659 A1 20010614 CA 2000-2393659 20000320
	EP 1235853 A1 20020904 EP 2000-919485 20000320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY
	AU 785297 B2 20070104 AU 2000-40167 20000320
	US 2005158831 A1 20050721 US 2005-87348 20050322
PRAI	US 1999-454223 A 19991209
	US 1998-111471P P 19981209
	WO 2000-US7380 W 20000320

CLASS	
	PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
WO 2001042298	ICM C07K014-00
	ICS A61K038-00
	IPCI C07K0014-00 [ICM,7]; A61K0038-00 [ICS,7]
	IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435
	[I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
CA 2393659	ECLA C07K014/525; C07K014/705Q
	IPCI C12N0015-09 [ICM,7]; A61K0038-00 [ICS,7]; C07K0014-00
	[ICS,7]; C07K0019-00 [ICS,7]
	IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435

		[I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
EP 1235853	IPCI	C07K0014-00 [ICM,6]; A61K0038-00 [ICS,6]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
AU 785297	IPCI	C07K0014-435 [I,C*]; A61K0039-00 [I,C*]; C07K0014-525 [I,A]; A61K0039-00 [I,A]; C07K0014-705 [I,A]
	ECLA	C07K014/525; C07K014/705Q
US 2005158831	IPCI	C12P0021-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-525 [ICS,7]; C07K0014-435 [ICS,7,C*]; C12N0001-21 [ICS,7]; C12N0015-74 [ICS,7]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
	NCL	435/069.500; 435/252.300; 435/320.100; 530/351.000; 536/023.500
	ECLA	C07K014/525; C07K014/705Q
AB	A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collecting fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.	
ST	vaccine adjuvant fusion protein CD40L RANKL TRANCE; tumor immunotherapeutic TNF collectin fusion protein; pulmonary surfactant protein D TNF CD40L	
IT	Glycoproteins, specific or class RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (CD40-L (antigen CD40 ligand), fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)	
IT	Antigens RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (OX-40, ligand or TNFSF4; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)	
IT	Cytokines RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (RANKL/TRANCE; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)	
IT	Surfactant proteins (pulmonary) RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (SP-D, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)	
IT	Tumor necrosis factors RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (TNFSF18 or AITRL or GITRL; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)	
IT	Tumor necrosis factors RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (TNFSF2; multimeric forms of TNF superfamily ligands as tumor	

immunotherapeutic agents)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNFSF4 or OX-40 ligand; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Immunostimulants
(adjuvants; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Neoplasm
(cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Agglutinins and Lectins
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(collectins, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphocyte
(immunocompetent; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Human immunodeficiency virus
(infected cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Proteins, general, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mammalian; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Alfalfa (*Medicago sativa*)
Animal
Antitumor agents
B cell (lymphocyte)
DNA sequences
Dendritic cell
Escherichia coli
Eukaryote (Eukaryotae)
Genetic vectors
Immunotherapy
Macrophage
Mammal (Mammalia)
Molecular cloning
Plant (Embryophyta)
Prokaryote
Protein sequences
Saccharomyces cerevisiae
Tobacco
Vaccines
Yeast
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphtoxin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Animal cell
(multiple receptors; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(multiple; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(open reading frame; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT DNA
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Genetic element
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(signal sequence, secretory; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structural; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(superfamily; fusion proteins; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcriptional; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Vaccines
(tumor; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Antitumor agents
(vaccines; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β ; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-84-5 344972-85-6 344972-86-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 139808-69-8P, GenBank X01393 140063-18-9P, GenBank D90224
147458-39-7P, GenBank L11016 148141-97-3P, GenBank X02910
149769-18-6P, GenBank L09753 224557-16-8P, GenBank AF125303
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-87-8 344972-88-9 344972-89-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344974-43-2 344974-44-3 344974-45-4 344974-46-5 344974-47-6

344974-48-7 344974-49-8 344974-50-1 344974-51-2 344974-52-3
344974-53-4 344974-54-5 344974-55-6

RL: PRP (Properties)

(unclaimed sequence; multimeric forms of TNF superfamily ligands)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Gires, O; EMBO J 1999, V16(20), P6131

(2) Pison, U; Eur J Clin Inv 1994, V24(9), P586 CAPLUS

=> s collectin AND TNFSF

L4 1 COLLECTIN AND TNFSF

=> d 14 all

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:435124 CAPLUS

DN 135:45182

ED Entered STN: 15 Jun 2001

TI Multimeric forms of TNF superfamily ligands

IN Kornbluth, Richard S.

PA USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K014-00

ICS A61K038-00

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042298	A1	20010614	WO 2000-US7380	20000320
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2393659	A1	20010614	CA 2000-2393659	20000320
	EP 1235853	A1	20020904	EP 2000-919485	20000320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AU 785297	B2	20070104	AU 2000-40167	20000320
	US 2005158831	A1	20050721	US 2005-87348	20050322
PRAI	US 1999-454223	A	19991209		
	US 1998-111471P	P	19981209		
	WO 2000-US7380	W	20000320		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001042298	ICM	C07K014-00	
	ICS	A61K038-00	
	IPCI	C07K0014-00 [ICM,7]; A61K0038-00 [ICS,7]	
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]	
CA 2393659	ECLA	C07K014/525; C07K014/705Q	
	IPCI	C12N0015-09 [ICM,7]; A61K0038-00 [ICS,7]; C07K0014-00 [ICS,7]; C07K0019-00 [ICS,7]	
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]	
EP 1235853	IPCI	C07K0014-00 [ICM,6]; A61K0038-00 [ICS,6]	
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]	
AU 785297	IPCI	C07K0014-435 [I,C*]; A61K0039-00 [I,C*]; C07K0014-525 [I,A]; A61K0039-00 [I,A]; C07K0014-705 [I,A]	
	ECLA	C07K014/525; C07K014/705Q	

US 2005158831 IPCI C12P0021-02 [ICM, 7]; C07H0021-04 [ICS, 7]; C07H0021-00
[ICS, 7, C*]; C07K0014-525 [ICS, 7]; C07K0014-435
[ICS, 7, C*]; C12N0001-21 [ICS, 7]; C12N0015-74 [ICS, 7]
IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435
[I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
NCL 435/069.500; 435/252.300; 435/320.100; 530/351.000;
536/023.500
ECLA C07K014/525; C07K014/705Q

- AB A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collecting fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.
- ST vaccine adjuvant fusion protein CD40L RANKL TRANCE; tumor immunotherapeutic TNF collectin fusion protein; pulmonary surfactant protein D TNF CD40L
- IT Glycoproteins, specific or class
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CD40-L (antigen CD40 ligand), fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)
- IT Antigens
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(OX-40, ligand or TNFSF4; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)
- IT Cytokines
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(RANKL/TRANCE; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)
- IT Surfactant proteins (pulmonary)
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SP-D, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)
- IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNFSF18 or AITRL or GITRL; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)
- IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNFSF2; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)
- IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TNFSF4 or OX-40 ligand; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Immunostimulants
(adjuvants; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Neoplasm
(cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Agglutinins and Lectins
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(collectins, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphocyte
(immunocompetent; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Human immunodeficiency virus
(infected cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Proteins, general, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mammalian; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Alfalfa (*Medicago sativa*)
Animal
Antitumor agents
B cell (lymphocyte)
DNA sequences
Dendritic cell
Escherichia coli
Eukaryote (Eukaryotae)
Genetic vectors
Immunotherapy
Macrophage
Mammal (Mammalia)
Molecular cloning
Plant (Embryophyta)
Prokaryote
Protein sequences
Saccharomyces cerevisiae
Tobacco
Vaccines
Yeast
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Fusion proteins (chimeric proteins)
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Animal cell
(multiple receptors; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(multiple; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(open reading frame; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT DNA
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Genetic element
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(signal sequence, secretory; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structural; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(superfamily; fusion proteins; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcriptional; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Vaccines
(tumor; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Antitumor agents
(vaccines; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β ; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-84-5 344972-85-6 344972-86-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 139808-69-8P, GenBank X01393 140063-18-9P, GenBank D90224
147458-39-7P, GenBank L11016 148141-97-3P, GenBank X02910
149769-18-6P, GenBank L09753 224557-16-8P, GenBank AF125303
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-87-8 344972-88-9 344972-89-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344974-43-2 344974-44-3 344974-45-4 344974-46-5 344974-47-6
344974-48-7 344974-49-8 344974-50-1 344974-51-2 344974-52-3
344974-53-4 344974-54-5 344974-55-6
RL: PRP (Properties)
(unclaimed sequence; multimeric forms of TNF superfamily ligands)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Gires, O; EMBO J 1999, V16(20), P6131
(2) Pison, U; Eur J Clin Inv 1994, V24(9), P586 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 16:43:03 ON 14 APR 2007)

FILE 'EMBASE, MEDLINE, CAPLUS, BIOSIS, SCISEARCH, DISSABS, REGISTRY'
ENTERED AT 16:43:24 ON 14 APR 2007

L1 4 S "COLLECTIN FUSION PROTEIN"
L2 3 S COLLECTIN AND TNF AND FUSION
L3 1 S COLLECTIN AND TNFSF AND FUSION
L4 1 S COLLECTIN AND TNFSF

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	93.17	93.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 16:46:29 ON 14 APR 2007